Bougherara L., Blache G., Arsene E., Jauffret C., Azais H., Laplane C., Hudry D., Atrous G., Knight S., Bresson L., Kakkos A., Narducci F., Leblanc E., Houvenaeghel G., Bats A. S., Lecuru F., Collinet P., Marchal F., Lambaudie E.
Robotic Surgery in Gynecologic Oncology.
Oncologie.
2016
;18
:287-297
Borget I., Dalle S., Leccia M., Dutriaux C., Stoebner P., Dalac S., Aubin F., Saiag P., Lacour J. P., Lesimple T., Dupuy A., Mortier L., Beylot-Barry M., Maubec E., Descamps V., Lok C., Stephan A., Guillot B., de Quatrebarbes J., Dreno B., Gally S., Mouri M., Allayous C., Kowal A., Porcher R., Lebbe C.
EFFECTIVENESS AND SAFETY OF VEMURAFENIB AS MONOTHERAPY IN UNRESECTABLE OR METASTATIC MELANOMA FROM AN ACADEMIC DATABASE: REAL WORLD DATA TO STRENGTHEN EVIDENCE FOR PAYER.
Value Health.
2016
;19
:A762-A763
Blank C., Lorigan P., Schachter J., Robert C., Ribas A., Long G. V., Arance A., Mortier L., Daud A., Carlino M. S., McNeil C., Lotem M., Larkin J., Neyns B., Petrella T. M., Hamid O., Zhou H., Ebbinghaus S., Ibrahim N., Grob J. J.
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006.
Melanoma Res..
2016
;26
:E117-E118
Beauval J. B. B., Ouzzane A., Ploussard G., Patard P. M., Gougeon A., Marcq G., Mathieu R., Vincendeau S., Hennequin C., Penna R. R., Cormier L., Azria D., Beuzeboc P., Artus P. M., Fromont G., De La Taille A., Roupret M., Soulie M., Salomon L., Mejean A., Rozet F.
A NEW SUBCLASSIFICATION SYSTEM FOR DECISION MAKING WITH INTERMEDIATE RISK PROSTATE CANCER PATIENTS TREATED BY RADICAL PROSTATECTOMY: A MULTICENTER STUDY.
J. Urol..
2016
;195
:E558-E559
Bassil A., Azais H., Wacrenier A., Mordon S., Frochot C., Collinet P., Betrouni N.
TOLERANCE OF PATHOGEN FREE TISSUES FOR PDT WITH FOLATE ADRESSED PS IN OVARIAN PERITONEAL CARCINOSIS.
Lasers Surg. Med..
2016
;48
:53-53
Basset-Seguin N., Sharpe H., Poulalhon N., Mortier L., Saiag P., Monestier S., Hou J., Bagot M., Guillot B., Robert C., Meyer N., Khammari A., Grange F., Dutriaux C., Dreno B., De Sauvage F.
Resistances to vismodegibs in a French case series of 207 patients with locally advanced basal cell carcinoma.
J. Clin. Oncol..
2016
;34
:9562-9562
Basset-Seguin N., Hansson J., Kunstfeld R., Grob J. J., Dreno B., Mortier L., Ascierto P. A., Dimier N., Fittipaldo A., Xynos I., Hauschild A.
Subgroup analysis of patients (pts) with Gorlin syndrome treated with vismodegib (VISMO) in the STEVIE study.
Ann. Oncol..
2016
;27
Basset-Seguin N., Dupuy A., Saiag P., Dalac-Rat S., Guillot B., Routier E., Leccia M. T., Duhamel A., Mirabel X., Benbouta I., Mirakovska L., Meddour D., Dib M., Mahmoudi A., Guerreschi P., Mortier L.
VISMONEO - a phase II study assessing vismodegib in the neoadjuvant treatment of locally advanced basal cell carcinoma - Patients characteristics.
Ann. Oncol..
2016
;27
Basset-Seguin N., Dupuy A., Saiag P., Dalac-Rat S., Guillot B., Routier E., Leccia M. T., Duhamel A., Mirabel X., Benbouta I., Mirakovska L., Meddour D., Dib M., Mahmoudi A., Guerreschi P., Mortier L.
VISMONEO - a phase II study assessing vismodegib in the neoadjuvant treatment of locally advanced basal cell carcinoma - patients characteristics.
Melanoma Res..
2016
;26
:E71-E72
